Trials / Active Not Recruiting
Active Not RecruitingNCT03085056
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
- Status
- Active Not Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib has on the shrinkage and growth of anaplastic thyroid cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trametinib | trametinib orally 2mg daily during each 4 week cycle |
| DRUG | Paclitaxel | paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks |
Timeline
- Start date
- 2017-03-15
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2017-03-21
- Last updated
- 2025-07-03
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03085056. Inclusion in this directory is not an endorsement.